Clinical Trial Update: A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma [NA]

View source ↗

Summary

A clinical trial is evaluating Alpha DaRT224 for recurrent cutaneous squamous cell carcinoma, focusing on efficacy and safety. The study is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma

Drugs mentioned

• Alpha DaRT224

Snippet

Sponsor: Alpha Tau Medical LTD. | Conditions: Recurrent Squamous Cell Carcinoma | NA | Status: RECRUITING